GSK completed the acquisition of BP asset IX from Boston Pharmaceuticals for $2bn.

GSK, a global biopharmaceutical company focused on research and development, completed the acquisition of BP asset IX, to obtain rights to efimosfermin alfa - a liver disease drug in late-stage trials, from Boston Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing highly engineered therapies, for $2bn. "The close of our acquisition for efimosfermin alfa represents a significant expansion of our hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease. Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029. We look forward to unlocking the potential of this medicine for patients," Kaivan Khavandi, GSK SVP & Global Head, Respiratory, Immunology & Inflammation R&D.